Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/
Accepted 2026-08-14 16:30:03 ET · period of report 2026-08-13 · accession 0001778623-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-14 16:30 | 2026-08-13 | DNTH | Veness Adam M | SVP, GC, Sec | M - OptEx | $18.17 | +15.0K | 15.0K | New | +$272.6K |
| D | 2026-08-14 16:30 | 2026-08-13 | DNTH | Veness Adam M | SVP, GC, Sec | M - OptEx | $0.00 | -15.0K | 73.2K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-13 | M | A | 15,000 | $18.17 | 15,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-08-13 | M | D | 15,000 | $0.00 | 73,240 | D | $18.17 · — to 2033-06-28 | 15,000 Common Stock | (F1) The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |